On August 6, the second-generation Flurbiprofen Patches (Zepolas®) from Beijing Tide Pharmaceutical, a core enterprise of SBP Group (1177.HK), received a drug registration certificate from the National Medical Products Administration (NMPA) and was granted a 4-year data protection period.

Sino Biopharmaceutical Limited (SBP Group, 1177.HK) and PT Tempo Scan Pacific Tbk (Tempo Scan) have jointly announced the formal signing of a joint venture agreement to establish PT TEMPO CTTQ BIOPHARMACEUTICAL INDONESIA (TCBI) in Indonesia. According to the agreement, SBP Group will hold a 51% stake in TCBI, and Tempo Scan will hold a 49% stake.

On July 22, the inaugural China Pharma Innovation Conference (CPIC 2026) opened at the Shanghai National Exhibition and Convention Center. The "CPIC 2026 Original New Drug Award" was officially announced at the conference. The first-in-class CDK2/4/6 inhibitor, Culmerciclib capsules (Saitanxin), self-developed by CTTQ, the core enterprise of SBP Group (1177.HK), received the award, showcasing Sino Biopharm's strength in pursuing source innovation to address significant clinical needs. Tse Hsin, Executive Director and Senior Vice President of SBP Group, attended the conference.

On July 8, Sino Biopharmaceutical Limited (1177.HK) announced that its subsidiary, Chia Tai Tianqing (CTTQ), has entered into an exclusive licensing agreement with AstraZeneca for SBP Group's self-developed PDE3/4 inhibitor (development code: TQC3721).

On July 8, SBP Group (1177.HK) announced a further expansion of its strategic partnership with GlaxoSmithKline (LSE/NYSE: GSK), through which its core enterprise Chia Tai Tianqing Pharmaceutical Group (CTTQ) will conduct the commercial operations for Trelegy Ellipta (Fluticasone Furoate, Umeclidinium Bromide and Vilanterol Trifenatate Powder for Inhalation, FF/UMEC/VI) and Anoro (Umeclidinium Bromide and Vilanterol Trifenatate Powder for Inhalation, UMEC/VI) in mainland China.

Following the release of the "Top 100 Chinese Pharmaceutical Innovation Enterprises 2026" list—where Sino Biopharmaceutical Limited (SBP Group, 1177.HK) has consistently ranked in the top three for many years—the 11th PDI Pharmaceutical R&D Innovation Conference announced the 2026 Pharmaceutical R&D Strength Ranking.

On July 1, 2026, on the occasion of the 105th anniversary of the founding of the Communist Party of China, the Hong Kong SAR Government announced the 2026 Honours List, the 29th such list since Hong Kong's return to China. Among the recipients, Ms. Cheng Cheung Ling, one of the founders of Chia Tai Pharmaceutical, founding president of the Hong Kong Chinese Association, President of Chia Tai Pharmaceutical Group, and Vice Chairwoman of the Board of Directors of Sino Biopharmaceutical Limited, was awarded the "Gold Bauhinia Star".

On June 25, E-Healthcare Manager released the "Top 100 Chinese Pharmaceutical Innovation Enterprises" list, with Sino Biopharmaceutical Limited (SBP Group, 1177.HK) once again ranking third.

The 2026 Summer Davos Forum is being held in Dalian, attracting over 1,700 representatives from more than 90 countries and regions, making it the largest "Annual Meeting of the New Champions" in history. On June 24, Premier Li Qiang of the State Council attended the opening ceremony of the 2026 Summer Davos Forum in Dalian and delivered a speech. On the same day, Eric Tse, Chief Executive Officer of Sino Biopharmaceutical Limited (SBP Group, 1177.HK), Chairman of Chia Tai Tianqing, and Chairman of Beijing Tide Pharmaceutical, was invited to attend the "How Far Can China’s Innovation Model Go? " roundtable forum and expressed his views.